ArticleEuropean journal of medical research2025
The multidimensional role of SLC16A4 in hepatocellular carcinoma in silico analysis: prognostic significance, metabolic pathways, and immune microenvironment regulation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LRP1 Activation Promotes Metabolic Reprogramming and Mrc1 Expression to Attenuate LPS-Induced Cognitive Deficits: An Integrated Omics Analysis.CNS neuroscience & therapeutics · 2026Article
- Integrative Mendelian Randomization and Pathomics Analysis Using Expression Quantitative Trait Loci and Genome-Wide Association Study Data Identifies Mismatch Repair Genes as Prognostic Biomarkers in Gastric Adenocarcinoma.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to analyze the expression patterns, clinical relevance, and biological functions of SLC16A4 across multiple cancer types, with a focus on liver hepatocellular carcinoma (LIHC) in silico analysis.
methodsWe conducted a pan-cancer analysis using data from TCGA and GTEx databases to evaluate SLC16A4 expression in various cancer types. The LIHC cohort was stratified based on SLC16A4 expression levels for further clinicopathological and survival analysis. Functional enrichment, immune infiltration, and RNA modification correlations were explored using bioinformatics tools, including GO, KEGG, GSEA, and ssGSEA.
resultsIn LIHC, SLC16A4 was markedly downregulated in tumor tissues compared to normal tissues, and its low expression correlated with advanced pathologic stages and poor histologic grades. Survival analysis revealed that high SLC16A4 expression was associated with improved overall survival and disease-specific survival in LIHC, with multivariate analysis confirming its role as an independent prognostic factor. Functional enrichment analysis linked SLC16A4 to key metabolic pathways. In addition, SLC16A4 expression was correlated with RNA modification genes and mismatch repair genes, suggesting its involvement in post-transcriptional regulation and genomic stability. Immune infiltration analysis revealed that high SLC16A4 expression was associated with increased infiltration of immune cells and regulating immune-related molecules, indicating its potential role in modulating the tumor immune microenvironment.
conclusionsSLC16A4 exhibits cancer-specific expression patterns and plays a multifaceted role in tumor progression, metabolism, and immune regulation. Its potential as a diagnostic and prognostic biomarker, particularly in LIHC, warrants further investigation. These findings highlight SLC16A4 as a promising target for future cancer research and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.